NCT04955743 2025-11-24Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaYale UniversityPhase 2 Terminated18 enrolled
NCT07011849 2025-08-13Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesM.D. Anderson Cancer CenterPhase 2 Withdrawn